Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALCNASDAQ:DARENASDAQ:KALANASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$1.80+5.3%$1.78$1.43▼$6.02$23.89M1.2445,893 shs3,846 shsDAREDaré Bioscience$2.90$2.92$2.67▼$6.24$25.67M1.236,275 shs17,685 shsKALAKALA BIO$4.04-1.2%$4.20$2.92▼$11.20$26.07M-1.9194,093 shs12,501 shsTRAWTraws Pharma$1.31+4.0%$1.80$0.97▼$19.44$7.29M1.59173,681 shs50,959 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica0.00%-10.00%+18.03%-23.40%-66.54%DAREDaré Bioscience0.00%+0.35%-3.33%-8.52%-39.58%KALAKALA BIO0.00%+10.08%+22.42%-39.16%-38.23%TRAWTraws Pharma0.00%+10.08%-14.38%-70.76%+130,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALCCalciMedica2.0041 of 5 stars3.55.00.00.00.01.70.0DAREDaré Bioscience1.3865 of 5 stars3.33.00.00.02.00.00.0KALAKALA BIO3.0666 of 5 stars3.51.00.04.41.10.00.6TRAWTraws Pharma0.7818 of 5 stars0.04.00.00.01.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 3.00Buy$18.00900.00% UpsideDAREDaré Bioscience 2.50Moderate Buy$12.00313.79% UpsideKALAKALA BIO 3.00Buy$13.50234.16% UpsideTRAWTraws Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRAW, KALA, CALC, and DARE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/15/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/4/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/1/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025DAREDaré BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/4/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A$1.42 per shareN/ADAREDaré Bioscience$25.91K990.58N/AN/A($0.61) per share-4.75KALAKALA BIO$3.89M6.70N/AN/A$2.79 per share1.45TRAWTraws Pharma$227K32.11N/AN/A$12.70 per share0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$34.36M-$1.56N/AN/AN/AN/A-164.24%-103.53%8/11/2025 (Estimated)DAREDaré Bioscience-$30.16M-$0.17N/AN/AN/A-191.65%N/A-18.98%8/11/2025 (Estimated)KALAKALA BIO-$42.20M-$8.24N/AN/AN/AN/A-448.61%-69.37%8/5/2025 (Estimated)TRAWTraws Pharma-$18.95M-$32.81N/AN/AN/A-62,294.25%N/A-822.38%8/13/2025 (Estimated)Latest TRAW, KALA, CALC, and DARE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TRAWTraws Pharma-$8.04$2.09+$10.13$2.09$0.06 million$0.06 million5/14/2025Q1 2025CALCCalciMedica-$0.43-$0.36+$0.07-$0.36N/AN/A5/13/2025Q1 2025DAREDaré Bioscience-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million3/31/2025Q4 2024DAREDaré Bioscience-$0.66-$0.64+$0.02-$0.64$1.00 million($0.06) million3/31/2025Q4 2024 & Study UpdateTRAWTraws Pharma-$7.00$95.66+$102.66$95.66$0.06 million$0.06 million3/28/2025Q4 2024KALAKALA BIO-$2.28-$1.74+$0.54-$1.74N/AN/A3/27/2025Q4 2024CALCCalciMedica-$0.48-$0.34+$0.14-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/ADAREDaré BioscienceN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedicaN/A4.154.15DAREDaré BioscienceN/A1.141.14KALAKALA BIO3.182.152.15TRAWTraws PharmaN/A1.071.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/ADAREDaré Bioscience6.70%KALAKALA BIO24.61%TRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%DAREDaré Bioscience4.00%KALAKALA BIO8.32%TRAWTraws Pharma13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3013.97 million7.88 millionNo DataDAREDaré Bioscience308.85 million8.35 millionNot OptionableKALAKALA BIO306.45 million5.58 millionNot OptionableTRAWTraws Pharma175.56 million3.15 millionOptionableTRAW, KALA, CALC, and DARE HeadlinesRecent News About These CompaniesTraws Pharma Unveils New Strategic Antiviral FocusMay 19, 2025 | tipranks.comTraws Pharma Highlights Q1 2025 Financial Progress and Antiviral DevelopmentsMay 18, 2025 | msn.comTraws Pharma Reports First Quarter 2025 Results and Business HighlightsMay 15, 2025 | globenewswire.comTraws Pharma Appoints New Chairman Amid Leadership ChangesApril 18, 2025 | tipranks.comThe Escalator: HHS, Spectrum Science, Alvotech and moreApril 3, 2025 | mmm-online.comTraws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID ProgramsApril 2, 2025 | msn.comTraws Pharma reports FY24 EPS ($35.21)April 1, 2025 | markets.businessinsider.comTraws Pharma, Inc. (TRAW) Virtual Investor Event TranscriptApril 1, 2025 | seekingalpha.comTraws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | finanznachrichten.deTraws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | markets.businessinsider.comTraws Pharma Announces CEO Transition as Werner Cautreels RetiresMarch 30, 2025 | msn.comTraws Pharma, Inc.: Traws Pharma Announces Management UpdatesMarch 29, 2025 | finanznachrichten.deTraws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAWMarch 29, 2025 | marketwatch.comTraws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAWMarch 29, 2025 | marketwatch.comTraws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19March 29, 2025 | msn.comTraws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEOMarch 29, 2025 | markets.businessinsider.comTraws Pharma Announces Management UpdatesMarch 28, 2025 | globenewswire.comTraws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 TreatmentMarch 27, 2025 | msn.comTraws Pharma Reports Promising Preclinical Results for Bird Flu TreatmentMarch 27, 2025 | msn.comTraws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ETMarch 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?TRAW, KALA, CALC, and DARE Company DescriptionsCalciMedica NASDAQ:CALC$1.80 +0.09 (+5.26%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.80 0.00 (0.00%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Daré Bioscience NASDAQ:DARE$2.90 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.87 -0.03 (-1.17%) As of 05/23/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.KALA BIO NASDAQ:KALA$4.04 -0.05 (-1.22%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.95 -0.09 (-2.23%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Traws Pharma NASDAQ:TRAW$1.31 +0.05 (+3.97%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.28 -0.03 (-1.91%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
